US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORUKA THERAPEUTICS INC

11.76

+0.86007.89%

Post-market: 11.760.00000.00%17:29 EDT

Volume:146.10K

Turnover:1.70M

Market Cap:440.30M

PE:-3.87

High:11.90

Open:10.79

Low:10.79

Close:10.90

Loading ...

Overview Company News Filings

Oruka Therapeutics Inc. Conducted Annual Stockholders Meeting

Oruka Therapeutics (ORKA) Gets a Buy from BTIG

BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target

MT Newswires Live

Oruka Therapeutics to Present at Jefferies Global Healthcare Conference in New York

Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment

MT Newswires Live

Oruka Therapeutics Inc: on Track to Initiate a Phase 2 Study in 1H 2026

THOMSON REUTERS

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-002, Its Novel Half-Life Extended Anti-Il-17a/F Antibody

THOMSON REUTERS

Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment

Oruka Therapeutics Price Target Maintained With a $40.00/Share by Wedbush

TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)

Oruka Therapeutics Reports Q1 2025 Results: $20.9M Net Cash Used in Operations; Strong $373M Cash Position

Oruka Therapeutics Inc: Expects to Share Efficacy and Response Duration Data From This Study in 2H 2026

THOMSON REUTERS

Oruka Therapeutics: Strong Cash Position of $373 Mln Provides Runway Through 2027, Over One Year Past Anticipated Orka-001 Phase 2a Data in Psoriasis

THOMSON REUTERS

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate

Simply Wall St.

Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance

Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals

MT Newswires Live

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Posts Q4 Net Loss

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORKA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":11.76,"timestamp":1750795200000,"preClose":10.9,"halted":0,"volume":146097,"hourTrading":{"tag":"盘后","latestPrice":11.76,"preClose":11.76,"latestTime":"17:29 EDT","volume":2388,"amount":28094.46,"timestamp":1750800558672},"delay":0,"floatShares":22632960,"shares":37440510,"eps":-3.042528,"marketStatus":"Not Yet Opened","change":0.86,"latestTime":"06-24 16:00:00 EDT","open":10.79,"high":11.9,"low":10.79,"amount":1703621.04633,"amplitude":0.101835,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.042528,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750838400000},"marketStatusCode":0,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":10.9,"postHourTrading":{"tag":"盘后","latestPrice":11.76,"preClose":11.76,"latestTime":"17:29 EDT","volume":2388,"amount":28094.46,"timestamp":1750800558672},"volumeRatio":0.838365,"impliedVol":0.5934,"impliedVolPercentile":0.3415},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":22632960,"roa":"--","roe":"--","lyrEps":-3.873702,"volumeRatio":0.838365,"shares":37440510,"dividePrice":0,"high":11.9,"amplitude":0.101835,"preClose":10.9,"low":10.79,"week52Low":5.485,"pbRate":"1.22","week52High":52.32,"institutionHeld":0.908,"latestPrice":11.76,"eps":-3.042528,"divideRate":0,"volume":146097,"delay":0,"ttmEps":-3.042528,"open":10.79,"prevYearClose":19.39,"prevWeekClose":11.68,"prevMonthClose":10.96,"prevQuarterClose":10.26,"fiveDayClose":12.43,"twentyDayClose":10.95,"sixtyDayClose":11.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540045497","title":"Oruka Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540045497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540045497?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:00","pubTimestamp":1748980849,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL36JrD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2540767180","title":"Oruka Therapeutics (ORKA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767180?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:16","pubTimestamp":1748862982,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA – Research Report) received a Buy rating and a $44.00 price target from BTIG analyst Julian Harrison today. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2537943179","title":"BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2537943179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537943179?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:33","pubTimestamp":1747913599,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has an average rating of buy and mean price target of $39.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","LENZ"],"gpt_icon":0},{"id":"2537328982","title":"Oruka Therapeutics to Present at Jefferies Global Healthcare Conference in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2537328982","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537328982?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:00","pubTimestamp":1747825224,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc., a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, will be presenting at the Jefferies Global Healthcare Conference in New York on June 4th, 2025. The presentation will highlight Oruka's advancements in treatments for conditions such as plaque psoriasis. A webcast and replay will be accessible through the Oruka investor events website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLpf2R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","ORKA","BK4588","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","BK4112","LU2095319765.USD","BK4585","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2537626418","title":"Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537626418","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537626418?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:46","pubTimestamp":1747777610,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  said late Tuesday it has commenced dosing healthy volunteers in its phase 1 trial for ORKA-002, a novel, long-acting monoclonal antibody designed to target IL-17A/F for the treatment of chronic skin diseases.The trial will assess the safety, tolerability, and pharmacokinetics of three subcutaneous dose levels in about 24 participants, the biotechnology company said, adding that preclinical data indicates that ORKA-002 may allow dosing just two to three times annually for psoriasis patients, representing a notable advancement over the current standard of care.The company said it expects releasing interim data by the end of 2025 and aims to begin a phase 2 trial for moderate-to-severe psoriasis in the first half of 2026. The planned phase 2 study will evaluate various dose levels, with the primary endpoint being PASI 100 at week 16.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2537623776","title":"Oruka Therapeutics Inc: on Track to Initiate a Phase 2 Study in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623776?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:33","pubTimestamp":1747773229,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS24D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2537623774","title":"Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-002, Its Novel Half-Life Extended Anti-Il-17a/F Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623774?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:33","pubTimestamp":1747773229,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS24D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2537628230","title":"Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537628230","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537628230?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:01","pubTimestamp":1747771272,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment. Oruka Therapeutics, Inc., a biotechnology company specializing in novel biologics for chronic skin diseases, has announced the commencement of its first clinical trial for ORKA-002. This trial involves dosing healthy volunteers with ORKA-002, a half-life extended monoclonal antibody targeting IL-17A/F, which is administered subcutaneously. The Phase 1 trial is designed as a double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 across three subcutaneous dose cohorts in approximately 24 participants. Interim data from this study is expected by the end of 2025. Oruka aims to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026, with a focus on assessing multiple dose levels and regimens.Disclaimer: This news brief was created by Public Technologies  using generativ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDLFnX7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","ORKA","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK4585","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2535827927","title":"Oruka Therapeutics Price Target Maintained With a $40.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535827927?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:04","pubTimestamp":1747321440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORKA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:04 ET (15:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","LENZ"],"gpt_icon":0},{"id":"2535887554","title":"TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535887554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535887554?lang=en_us&edition=fundamental","pubTime":"2025-05-15 07:56","pubTimestamp":1747266990,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report). The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-oruka-therapeutics-orka?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-oruka-therapeutics-orka?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","ORKA","BK4139","BK4566","BK4207","BK4585","COWN","TD"],"gpt_icon":0},{"id":"2535007212","title":"Oruka Therapeutics Reports Q1 2025 Results: $20.9M Net Cash Used in Operations; Strong $373M Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007212","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007212?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:21","pubTimestamp":1747254062,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL9YJMMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","ORKA","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4588","BK4139"],"gpt_icon":0},{"id":"2535071300","title":"Oruka Therapeutics Inc: Expects to Share Efficacy and Response Duration Data From This Study in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535071300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535071300?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA18LQC2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2535007132","title":"Oruka Therapeutics: Strong Cash Position of $373 Mln Provides Runway Through 2027, Over One Year Past Anticipated Orka-001 Phase 2a Data in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007132?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA18LQC2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2531781612","title":"Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781612?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., April 29, 2025  -- Oruka Therapeutics, Inc.  , a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT.Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oruka-therapeutics-present-bank-america-110000866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFXG1179.USD","LU0106831901.USD","BK4581","LU0310800965.SGD","LU2129689514.USD","IE00B7SZLL34.SGD","LU0098860793.USD","LU1880398471.USD","IE00BLSP4452.SGD","LU1496350171.SGD","IE00B19Z3581.USD","BK4585","LU1363072403.SGD","LU0130103400.USD","LU1201861249.SGD","LENZ","LU0070302665.USD","LU0321505868.SGD","LU0417517546.SGD","LU0477156797.USD","LU0683600562.USD","LU2129689431.USD","BK4207","LU0320765646.SGD","BAC","BK4139","LU0149725797.USD","LU0314106906.USD","LU0130102774.USD","LU0868494617.USD","LU0321505439.SGD","LU1201861165.SGD","BK4534","BK4504","LU0052756011.USD","IE0002270589.USD","LU0648001328.SGD","LU0306806265.USD","ORKA","LU0320765489.SGD","BK4553","LU0971096721.USD","LU1880398554.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU0128525689.USD","LU1894683348.USD","LU2129689605.HKD","LU1791807156.HKD","LU0256863902.USD"],"gpt_icon":0},{"id":"2529721198","title":"Oruka Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2529721198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529721198?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:17","pubTimestamp":1745234225,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Oruka Therapeutics Inc ORKA.OQ ORKA.O is expected to report resultson April 23 (estimated) for the period ending Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nL8N3QZ0FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA"],"gpt_icon":0},{"id":"2517410724","title":"We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517410724","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517410724?lang=en_us&edition=fundamental","pubTime":"2025-03-08 21:49","pubTimestamp":1741441796,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So should Oruka Therapeutics  shareholders be worried about its cash burn?In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.Check out our latest analysis for Oruka Therapeutics. When Might Oruka Therapeutics Run Out Of Money?If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-oruka-134956436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","PSQ","NVIW.SI","QLD","BK4139","ORKA","SQQQ","BK4588","IE00BGHQF748.EUR","TQQQ","LU2210149790.SGD","TSYW.SI","IE00B3QW5Z07.USD","BK4112","USJW.SI","NQmain","MNQmain",".IXIC","IE00BKPKM429.USD","BK4585","USAW.SI","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","QID"],"gpt_icon":1},{"id":"2517041562","title":"Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2517041562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517041562?lang=en_us&edition=fundamental","pubTime":"2025-03-08 14:01","pubTimestamp":1741413661,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc. (ORKA) has disclosed a new risk, in the Trade Secrets category. Oruka Therapeutics, Inc. faces significant business risks ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oruka-therapeutics-at-risk-navigating-licensing-challenges-and-partner-reliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oruka-therapeutics-at-risk-navigating-licensing-challenges-and-partner-reliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA","LENZ"],"gpt_icon":0},{"id":"2517430777","title":"Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430777","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517430777?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:25","pubTimestamp":1741364755,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  said Friday that preclinical data on its monoclonal antibody ORKA-002 support potential extended dosing intervals and show equivalent potency to bimekizumab in plaque psoriasis.The company said ORKA-002 demonstrated a half-life of over 30 days in non-human primates, more than three times longer than bimekizumab and indicating a human half-life of about 50 days could allow dosing once every four months while a human half-life of approximately 75 days could allow dosing twice a year.Oruka also said ORKA-002, which is being developed to potentially treat chronic skin diseases including plaque psoriasis, exhibits comparable binding affinity and potency to bimekizumab, thus reducing development risks.The company said it expects to conduct a clinical trial of ORKA-002 and dose the first subject in Q3.Price: 10.25, Change: +0.18, Percent Change: +1.79","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2517276438","title":"Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517276438","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517276438?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:30","pubTimestamp":1741354200,"startTime":"0","endTime":"0","summary":"Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimeki","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038935/0/en/Oruka-Therapeutics-Announces-Preclinical-Data-for-ORKA-002-at-the-2025-American-Academy-of-Dermatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","BK4181","BK4139","PK","AFG","ORKA","BK4117","BK4218"],"gpt_icon":0},{"id":"2517911916","title":"Oruka Therapeutics Posts Q4 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911916","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911916?lang=en_us&edition=fundamental","pubTime":"2025-03-07 06:17","pubTimestamp":1741299433,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  reported a Q4 net loss late Thursday of $0.49 per diluted share.Analysts polled by FactSet expected a loss of $0.74.Oruka did not provide revenue for the quarter and year-ago figures.The company said its cash, cash equivalents and marketable securities at the end of 2024 were $394 million and are projected to fund the company through 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","LENZ","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12},{"date":"2024-08-29","symbol":"ORKA","amount":1.613,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-26","defaultRemindTime":1724938200000,"name":"方舟生物医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-28","payableDate":"2024-08-26","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-28"},{"market":"US","date":"2024-08-01","symbol":"ORKA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-04-25","symbol":"ORKA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-02-01","symbol":"ORKA","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":9,"updateTime":1747972800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2025-06-23","current":-4.154632,"percent":0.5,"low":-5.124049,"twenty":-4.541137,"median":-4.154632,"eighty":-3.778351,"high":-2.779284,"avg":-4.120645,"sd":0.513848,"marketCap":437305156},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-23","current":-4.154632,"twenty":-4.541137,"median":-4.154632,"eighty":-3.778351,"marketCap":437305156}],"updateTime":1750805368119}}}